← Back to Clinical Trials
Recruiting NCT07065747

NCT07065747 Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07065747
Status Recruiting
Phase
Sponsor Oregon Health and Science University
Condition Anterior Uveitis (AU)
Study Type OBSERVATIONAL
Enrollment 125 participants
Start Date 2024-09-01
Primary Completion 2026-09

Eligibility & Interventions

Sex All sexes
Min Age 5 Years
Max Age 85 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 125 participants in total. It began in 2024-09-01 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to determine if it's possible to use a high resolution imaging device called optical coherence tomography (OCT) to develop an unbiased, standard method of counting and categorizing the various types of cells and proteins found in an eye condition called anterior uveitis. Anterior uveitis is a type of inflammation in the eye that can be caused by many different diseases of the body.

Eligibility Criteria

Inclusion Criteria: 1. Uveitis Group: Eyes with active intraocular inflammation and a clinical diagnose of spondyloarthritis/HLA-B27 associated anterior uveitis, Juvenile Idiopathic Arthritis (JIA) associated chronic anterior uveitis, Herpes Simplex Virus (HSV) anterior uveitis, Birdshot chorioretinitis, Behcet disease uveitis, sarcoidosis associated uveitis, uveitis of any additional type, or uveitis masquerade. 2. Posterior Vitreous Detachment Group: Eyes with vitreous floaters and posterior vitreous detachment (PVD). 3. Healthy/Control Group: Healthy eyes with no history of uveitis, PVD, or previous eye surgery. Exclusion Criteria: 1. Inability to give informed consent. 2. Inability to maintain stable fixation for OCT imaging. 3. Inability to commit to required visits to complete the study. 4. Pregnancy and breastfeeding.

Contact & Investigator

Central Contact

Humberto Martinez, COT, MBA

✉ martinhu@ohsu.edu

📞 503-494-7712

Principal Investigator

Yan Li, PhD

PRINCIPAL INVESTIGATOR

Oregon Health and Science University

Frequently Asked Questions

Who can join the NCT07065747 clinical trial?

This trial is open to participants of all sexes, aged 5 Years or older, up to 85 Years, studying Anterior Uveitis (AU). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07065747 currently recruiting?

Yes, NCT07065747 is actively recruiting participants. Contact the research team at martinhu@ohsu.edu for enrollment information.

Where is the NCT07065747 trial being conducted?

This trial is being conducted at Portland, United States.

Who is sponsoring the NCT07065747 clinical trial?

NCT07065747 is sponsored by Oregon Health and Science University. The principal investigator is Yan Li, PhD at Oregon Health and Science University. The trial plans to enroll 125 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology